SAN DIEGO, April 27, 2011 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that more than half of the subjects in the Phase 1 trial of the company’s Vaxfectin®-formulated vaccine for H1N1 pandemic influenza generated neutralizing antibodies of the type expected to provide protection against the disease. The vaccine was well-tolerated. Vical was the first company to manufacture a vaccine against the H1N1 influenza virus and the first to conduct animal testing during the 2009 outbreaks, and these latest results demonstrated the safety and immunogenicity of that same vaccine in humans.
